Sign in
Taking peoplePhase 3

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

Key facts

Who runs it
Qilu Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
80 people, planned
Started
12 Apr 2025
Expected to end
Apr 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Meropenem and Pralurbactam
  • Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
Record updated
30 July 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Hospitalized male or female≥18 and ≤80 years of age,
  • Participant must have a diagnosis of an infection (HABP/VABP, cUTI, cIAI, BSI) due to confirmed Carbapenem-Resistant Enterobacteriaceae infection, requiring administration of IV antibacterial therapy
  • Participant who had received appropriate prior empiric antibacterial therapy for a carbapenem-resistant pathogen must meet at least 1 of the following criteria: no or no more than 24h; worsening of objective symptoms or signs after at least 48 hours of antibacterial therapy; no change of objective symptoms or signs after at least 72 hours of antibacterial therapy
  • The estimated survival time is more than 28 days
  • Understand and abide by the research procedures and methods, voluntarily participate in this research, and sign an informed consent form

Who cannot take part

  • Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices
  • Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Participants who need more than 3 systemic antibiotics as part of best available treatment (BAT)
  • Participant is expected to require more than 21 days of treatment
  • Acute Physiology and Chronic Health Evaluation (APACHE) II score >30 using the most recent available data

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), and Bloodstream Infection (BSI).

The 2 groups in the trial

  • Meropenem and PralurbactamTreatment being tested

    Meropenem and Pralurbactam (180min infusion)

  • Best Available TherapyExisting treatment, for comparison

    Subjects will receive Best Available Therapy (IV antibiotics)

    Treatment: Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled, Parallel-design Clinical Study to Evaluate the Efficacy and Safety of Meropenem and Pralubactam for Injection in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
Criteria questions
Built from NCT07089186, who can take part
Record updated
30 July 2025